Abstract
Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain “immunogenic” forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain “danger” signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed.
Keywords: Chemotherapy, chemomodulation, chemoimmunomodulation, immunostimulation, immunosuppression, paclitaxel
Current Medicinal Chemistry
Title:ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Volume: 19 Issue: 12
Author(s): M. R. Shurin, H. Naiditch, D. W. Gutkin, V. Umansky and G. V. Shurin
Affiliation:
Keywords: Chemotherapy, chemomodulation, chemoimmunomodulation, immunostimulation, immunosuppression, paclitaxel
Abstract: Since 1948, when Farber et al. introduced aminopterin, the first chemotherapeutic agent, more than 100 such agents have come into use. Initially, antitumor chemotherapies were thought to produce only antiproliferative or cytotoxic effects on dividing tumor cells as it was often associated with the damage to healthy tissues and the development of resistant tumor clones. However, that view has been changing as a consequence of recent demonstrations that several antineoplastic drugs, even at low doses, have antiangiogenic and sometimes immunomodulating effects. In addition, new studies indicate that lowering the dose of conventional cytotoxic agents and combining chemotherapy with other modalities may not only decrease the toxicity of conventional chemotherapy, but also up-regulate the efficacy of different anticancer therapies. Giving chemotherapy in this manner has several potential advantages, including impediment of the onset of mutation-dependent mechanisms of acquired drug resistance and increase in the efficacy and durability of combinatorial therapeutic modalities. Certain “immunogenic” forms of cancer chemotherapy may cause indirect activation of immune cells due to the accessibility of tumor antigens and certain “danger” signals. Furthermore, new findings indicate that several chemotherapeutic agents can directly activate immune cells when used in ultra low noncytotoxic concentrations, the new phenomenon that was termed chemoimmunomodulation. The goal of this review is to analyze the immune modulating properties of antineoplastic chemotherapeutic agents and present new evidence of the immunostimulating potentials of several agents used in low and ultra low nontoxic doses. Therapeutic potentials of combined chemo-immunotherapeutic regimens have been extensively reviewed in a variety of recent publications and will not be discussed.
Export Options
About this article
Cite this article as:
R. Shurin M., Naiditch H., W. Gutkin D., Umansky V. and V. Shurin G., ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents, Current Medicinal Chemistry 2012; 19 (12) . https://dx.doi.org/10.2174/092986712800099785
DOI https://dx.doi.org/10.2174/092986712800099785 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice
Current Pediatric Reviews Flavonoids on Allergy
Current Pharmaceutical Design Access to Medicines and the Safety of the People
Reviews on Recent Clinical Trials An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Pharmacogenomics in the Americas: The Impact of Genetic Admixture
Current Drug Targets Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews Editorial (Thematic Issue: Recent Advances in Vaccine Delivery)
Current Drug Therapy Nanocarriers as Prospective Approach in Effective Management of Acne Vulgaris
Micro and Nanosystems HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design A Classification Method for Microarrays Based on Diversity
Current Bioinformatics Use of Transgenic Mouse Models to Understand the Origins of Familial Pulmonary Fibrosis
Current Pharmaceutical Biotechnology An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry AAV-Mediated Gene Transfer for Treatment of Hemophilia
Current Gene Therapy Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Oleic Acid Protects Against Oxidative Stress Exacerbated by Cytarabine and Doxorubicin in Rat Brain
Anti-Cancer Agents in Medicinal Chemistry Saturation of the Human Phenome
Current Genomics Fanconi Anemia Proteins, DNA Interstrand Crosslink Repair Pathways, and Cancer Therapy
Current Cancer Drug Targets Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design